Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Apr 22;26(9):3927.
doi: 10.3390/ijms26093927.

The Genetic Background of the Immunological and Inflammatory Aspects of Progressive Supranuclear Palsy

Piotr Alster  1 , Natalia Madetko-Alster  1
Affiliations
Review

The Genetic Background of the Immunological and Inflammatory Aspects of Progressive Supranuclear Palsy

Piotr Alster et al. Int J Mol Sci. .

Abstract

Progressive supranuclear palsy (PSP) is a neurodegenerative disease, classified as an atypical Parkinsonian syndrome, that has been pathologically and clinically defined. The histopathological aspects of the disease include tufted astrocytes, while the clinical features involve oculomotor dysfunction, postural instability, akinesia, cognitive impairment, and language difficulties. Although PSP is generally considered a sporadic disease, interest is growing in its genetics, with contemporary research focusing on familial backgrounds and neuroinflammation. Indeed, microglial activation and other inflammatory mechanisms of PSP pathogenesis have been extensively analyzed using genetic examinations to identify the factors impacting neurodegeneration. As such, this review aims to elaborate on recent findings in this field.

Keywords: MAPT; PSP; atypical parkinsonism; genetics; microglia.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted without any commercial or financial relationship that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Aspects of immune molecular pathogenesis of progressive supranuclear palsy (PSP).
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Yoshida M. Astrocytic inclusions in progressive supranuclear palsy and corticobasal degeneration. Neuropathology. 2014;34:555–570. doi: 10.1111/neup.12143. - DOI - PubMed
    1. Höglinger G.U., Respondek G., Stamelou M., Kurz C., Josephs K.A., Lang A.E., Mollenhauer B., Müller U., Nilsson C., Whitwell J.L., et al. Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. Mov. Disord. 2017;32:853–864. doi: 10.1002/mds.26987. - DOI - PMC - PubMed
    1. Debnath M., Dey S., Sreenivas N., Pal P.K., Yadav R. Genetic and Epigenetic Constructs of Progressive Supranuclear Palsy. Ann. Neurosci. 2022;29:177–188. doi: 10.1177/09727531221089396. - DOI - PMC - PubMed
    1. Alster P., Madetko N., Koziorowski D., Friedman A. Progressive Supranuclear Palsy-Parkinsonism Predominant (PSP-P)-A Clinical Challenge at the Boundaries of PSP and Parkinson’s Disease (PD) Front. Neurol. 2020;11:180. doi: 10.3389/fneur.2020.00180. - DOI - PMC - PubMed
    1. Alster P., Otto-Ślusarczyk D., Kutyłowski M., Migda B., Wiercińska-Drapało A., Jabłońska J., Struga M., Madetko-Alster N. The associations between common neuroimaging parameters of Progressive Supranuclear Palsy in magnetic resonance imaging and non-specific inflammatory factors—Pilot study. Front. Immunol. 2024;15:1458713. doi: 10.3389/fimmu.2024.1458713. - DOI - PMC - PubMed

MeSH terms